Trial Profile
A Dose Block-randomized, Double Blind, Placebo Controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Dosing of HL217 Eye Drop in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Apr 2019
Price :
$35
*
At a glance
- Drugs HL-217 (Primary)
- Indications Retinal disorders
- Focus Adverse reactions
- Sponsors Hanlim Pharmaceutical
- 28 Mar 2019 Status changed from active, no longer recruiting to completed.
- 04 Sep 2018 New trial record